Literature DB >> 16091306

Kinetic and stability analysis of PKU mutations identified in BH4-responsive patients.

Belén Pérez1, Lourdes R Desviat, Paulino Gómez-Puertas, Aurora Martínez, Rymond C Stevens, Magdalena Ugarte.   

Abstract

From all the different molecular mechanisms put forward to explain the basis of BH4 responsiveness in PKU patients, a clear picture is now emerging based on the results from expression studies performed with a number of missense mutations identified in patients with a positive response in BH4 loading tests. Two of the proposed mechanisms, namely decreased binding affinity of the mutant proteins for the natural cofactor and stabilization effect of BH4, have been confirmed for several PKU mutations and the results are reviewed here. The actual view supports a multifactorial basis of the response, highlighting the necessity of detailed in vitro characterization of each mutant PAH protein. Several of the confirmed molecular mechanisms may be operating simultaneously, as exemplified in the data presented, and this may result in different degrees of BH4 responsiveness.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16091306     DOI: 10.1016/j.ymgme.2005.06.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  18 in total

1.  Protein stability and in vivo concentration of missense mutations in phenylalanine hydroxylase.

Authors:  Zhen Shi; Jenn Sellers; John Moult
Journal:  Proteins       Date:  2011-09-21

Review 2.  Phenylketonuria: a 21st century perspective.

Authors:  Francjan J van Spronsen
Journal:  Nat Rev Endocrinol       Date:  2010-09       Impact factor: 43.330

3.  Cystathionine beta-synthase mutants exhibit changes in protein unfolding: conformational analysis of misfolded variants in crude cell extracts.

Authors:  Aleš Hnízda; Vojtěch Jurga; Kateřina Raková; Viktor Kožich
Journal:  J Inherit Metab Dis       Date:  2011-11-09       Impact factor: 4.982

4.  Molecular Genetics and Genotype-Based Estimation of BH4-Responsiveness in Serbian PKU Patients: Spotlight on Phenotypic Implications of p.L48S.

Authors:  Maja Djordjevic; Kristel Klaassen; Adrijan Sarajlija; Natasa Tosic; Branka Zukic; Bozica Kecman; Milena Ugrin; Vesna Spasovski; Sonja Pavlovic; Maja Stojiljkovic
Journal:  JIMD Rep       Date:  2012-10-13

5.  Clinical therapeutics for phenylketonuria.

Authors:  Jaspreet Singh Kochhar; Sui Yung Chan; Pei Shi Ong; Lifeng Kang
Journal:  Drug Deliv Transl Res       Date:  2012-08       Impact factor: 4.617

6.  Twisting of the DNA-binding surface by a beta-strand-bearing proline modulates DNA gyrase activity.

Authors:  Tung-Ju Hsieh; Tien-Jui Yen; Te-Sheng Lin; Hsun-Tang Chang; Shu-Yun Huang; Chun-Hua Hsu; Lynn Farh; Nei-Li Chan
Journal:  Nucleic Acids Res       Date:  2010-03-09       Impact factor: 16.971

7.  The Missense p.S231F phenylalanine hydroxylase gene mutation causes complete loss of enzymatic activity in vitro.

Authors:  Maja Stojiljkovic; Belén Pérez; Lourdes R Desviat; Cristina Aguado; Magdalena Ugarte; Sonja Pavlovic
Journal:  Protein J       Date:  2009-08       Impact factor: 2.371

Review 8.  Lending a helping hand, screening chemical libraries for compounds that enhance beta-hexosaminidase A activity in GM2 gangliosidosis cells.

Authors:  Michael B Tropak; Don Mahuran
Journal:  FEBS J       Date:  2007-10       Impact factor: 5.542

9.  Loss of function in phenylketonuria is caused by impaired molecular motions and conformational instability.

Authors:  Søren W Gersting; Kristina F Kemter; Michael Staudigl; Dunja D Messing; Marta K Danecka; Florian B Lagler; Christian P Sommerhoff; Adelbert A Roscher; Ania C Muntau
Journal:  Am J Hum Genet       Date:  2008-06-05       Impact factor: 11.025

10.  The prevalence of folate-remedial MTHFR enzyme variants in humans.

Authors:  Nicholas J Marini; Jennifer Gin; Janet Ziegle; Kathryn Hunkapiller Keho; David Ginzinger; Dennis A Gilbert; Jasper Rine
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-03       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.